nodes	percent_of_prediction	percent_of_DWPC	metapath
Amiloride—PLAU—urinary bladder cancer	0.727	1	CbGaD
Amiloride—SCNN1G—prostate gland—urinary bladder cancer	0.00358	0.0332	CbGeAlD
Amiloride—SCNN1D—prostate gland—urinary bladder cancer	0.00358	0.0332	CbGeAlD
Amiloride—AOC1—prostate gland—urinary bladder cancer	0.00352	0.0326	CbGeAlD
Amiloride—ASIC1—prostate gland—urinary bladder cancer	0.00352	0.0326	CbGeAlD
Amiloride—SLC9A1—prostate gland—urinary bladder cancer	0.00337	0.0312	CbGeAlD
Amiloride—PLAU—prostate gland—urinary bladder cancer	0.00319	0.0296	CbGeAlD
Amiloride—SCNN1G—seminal vesicle—urinary bladder cancer	0.00303	0.0281	CbGeAlD
Amiloride—SCNN1B—prostate gland—urinary bladder cancer	0.00303	0.0281	CbGeAlD
Amiloride—SCNN1A—prostate gland—urinary bladder cancer	0.0028	0.0259	CbGeAlD
Amiloride—PLAU—seminal vesicle—urinary bladder cancer	0.0027	0.025	CbGeAlD
Amiloride—SCNN1D—epithelium—urinary bladder cancer	0.00263	0.0244	CbGeAlD
Amiloride—SLC9A1—epithelium—urinary bladder cancer	0.00248	0.023	CbGeAlD
Amiloride—SCNN1G—renal system—urinary bladder cancer	0.00244	0.0226	CbGeAlD
Amiloride—SCNN1G—urethra—urinary bladder cancer	0.0024	0.0222	CbGeAlD
Amiloride—AOC1—renal system—urinary bladder cancer	0.0024	0.0222	CbGeAlD
Amiloride—SLC9A1—smooth muscle tissue—urinary bladder cancer	0.00239	0.0221	CbGeAlD
Amiloride—AOC1—urethra—urinary bladder cancer	0.00236	0.0218	CbGeAlD
Amiloride—PLAU—epithelium—urinary bladder cancer	0.00235	0.0218	CbGeAlD
Amiloride—SLC9A1—renal system—urinary bladder cancer	0.0023	0.0213	CbGeAlD
Amiloride—PLAU—smooth muscle tissue—urinary bladder cancer	0.00226	0.021	CbGeAlD
Amiloride—SCNN1B—epithelium—urinary bladder cancer	0.00223	0.0206	CbGeAlD
Amiloride—PLAU—renal system—urinary bladder cancer	0.00218	0.0202	CbGeAlD
Amiloride—PLAU—urethra—urinary bladder cancer	0.00214	0.0198	CbGeAlD
Amiloride—SCNN1B—renal system—urinary bladder cancer	0.00206	0.0191	CbGeAlD
Amiloride—SCNN1A—epithelium—urinary bladder cancer	0.00206	0.0191	CbGeAlD
Amiloride—SCNN1B—urethra—urinary bladder cancer	0.00203	0.0188	CbGeAlD
Amiloride—SCNN1D—female reproductive system—urinary bladder cancer	0.00196	0.0181	CbGeAlD
Amiloride—SCNN1G—female reproductive system—urinary bladder cancer	0.00196	0.0181	CbGeAlD
Amiloride—AOC1—female reproductive system—urinary bladder cancer	0.00192	0.0178	CbGeAlD
Amiloride—ASIC1—female reproductive system—urinary bladder cancer	0.00192	0.0178	CbGeAlD
Amiloride—SCNN1A—renal system—urinary bladder cancer	0.00191	0.0177	CbGeAlD
Amiloride—SCNN1A—urethra—urinary bladder cancer	0.00187	0.0174	CbGeAlD
Amiloride—SLC9A1—female reproductive system—urinary bladder cancer	0.00184	0.0171	CbGeAlD
Amiloride—SCNN1G—vagina—urinary bladder cancer	0.00177	0.0164	CbGeAlD
Amiloride—PLAU—female reproductive system—urinary bladder cancer	0.00174	0.0162	CbGeAlD
Amiloride—AOC1—vagina—urinary bladder cancer	0.00174	0.0161	CbGeAlD
Amiloride—SCNN1B—female reproductive system—urinary bladder cancer	0.00165	0.0153	CbGeAlD
Amiloride—PLAU—vagina—urinary bladder cancer	0.00158	0.0146	CbGeAlD
Amiloride—SCNN1A—female reproductive system—urinary bladder cancer	0.00153	0.0142	CbGeAlD
Amiloride—SCNN1B—vagina—urinary bladder cancer	0.00149	0.0139	CbGeAlD
Amiloride—SCNN1D—lymph node—urinary bladder cancer	0.00114	0.0106	CbGeAlD
Amiloride—AOC1—lymph node—urinary bladder cancer	0.00112	0.0104	CbGeAlD
Amiloride—ASIC1—lymph node—urinary bladder cancer	0.00112	0.0104	CbGeAlD
Amiloride—SLC22A4—prostate gland—urinary bladder cancer	0.00112	0.0104	CbGeAlD
Amiloride—SLC9A1—lymph node—urinary bladder cancer	0.00108	0.00998	CbGeAlD
Amiloride—SLC22A2—renal system—urinary bladder cancer	0.00103	0.00955	CbGeAlD
Amiloride—PLAU—lymph node—urinary bladder cancer	0.00102	0.00946	CbGeAlD
Amiloride—SCNN1B—lymph node—urinary bladder cancer	0.000967	0.00897	CbGeAlD
Amiloride—SLC22A4—seminal vesicle—urinary bladder cancer	0.000948	0.00879	CbGeAlD
Amiloride—SCNN1A—lymph node—urinary bladder cancer	0.000893	0.00828	CbGeAlD
Amiloride—SLC22A4—renal system—urinary bladder cancer	0.000764	0.00708	CbGeAlD
Amiloride—SLC22A1—renal system—urinary bladder cancer	0.000727	0.00674	CbGeAlD
Amiloride—SLC22A4—female reproductive system—urinary bladder cancer	0.000612	0.00567	CbGeAlD
Amiloride—SLC22A4—vagina—urinary bladder cancer	0.000553	0.00513	CbGeAlD
Amiloride—PLAU—amb2 Integrin signaling—MMP9—urinary bladder cancer	0.000543	0.00649	CbGpPWpGaD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CXCL8—urinary bladder cancer	0.000535	0.00639	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—CDK4—urinary bladder cancer	0.000531	0.00635	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—ESR1—urinary bladder cancer	0.000529	0.00632	CbGpPWpGaD
Amiloride—SLC22A1—vagina—urinary bladder cancer	0.000527	0.00488	CbGeAlD
Amiloride—PLAU—Endochondral Ossification—FGFR3—urinary bladder cancer	0.00051	0.0061	CbGpPWpGaD
Amiloride—ASIC2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000505	0.00603	CbGpPWpGaD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCND1—urinary bladder cancer	0.000498	0.00595	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—CDH1—urinary bladder cancer	0.000494	0.0059	CbGpPWpGaD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—urinary bladder cancer	0.000484	0.00578	CbGpPWpGaD
Amiloride—SCNN1D—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000469	0.00561	CbGpPWpGaD
Amiloride—SCNN1B—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000469	0.00561	CbGpPWpGaD
Amiloride—SCNN1G—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000469	0.00561	CbGpPWpGaD
Amiloride—ASIC1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000469	0.00561	CbGpPWpGaD
Amiloride—SCNN1A—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000469	0.00561	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—RB1—urinary bladder cancer	0.000462	0.00552	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—ESR1—urinary bladder cancer	0.000462	0.00551	CbGpPWpGaD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—EP300—urinary bladder cancer	0.000459	0.00548	CbGpPWpGaD
Amiloride—SLC9A1—RhoA signaling pathway—PTEN—urinary bladder cancer	0.000456	0.00545	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—ATM—urinary bladder cancer	0.00045	0.00538	CbGpPWpGaD
Amiloride—SLC9A1—Endothelins—RHOA—urinary bladder cancer	0.000441	0.00527	CbGpPWpGaD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP9—urinary bladder cancer	0.000437	0.00522	CbGpPWpGaD
Amiloride—PLAU—Endochondral Ossification—IGF1—urinary bladder cancer	0.000429	0.00513	CbGpPWpGaD
Amiloride—SLC9A1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000428	0.00511	CbGpPWpGaD
Amiloride—PLAU—amb2 Integrin signaling—TNF—urinary bladder cancer	0.000418	0.005	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—SOD2—urinary bladder cancer	0.000414	0.00494	CbGpPWpGaD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—SRC—urinary bladder cancer	0.000403	0.00482	CbGpPWpGaD
Amiloride—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.000401	0.00479	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—CREBBP—urinary bladder cancer	0.000391	0.00467	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—RB1—urinary bladder cancer	0.00039	0.00465	CbGpPWpGaD
Amiloride—SLC22A4—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000386	0.00461	CbGpPWpGaD
Amiloride—SCNN1G—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000383	0.00457	CbGpPWpGaD
Amiloride—ASIC1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000383	0.00457	CbGpPWpGaD
Amiloride—SCNN1A—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000383	0.00457	CbGpPWpGaD
Amiloride—SCNN1B—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000383	0.00457	CbGpPWpGaD
Amiloride—SCNN1D—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000383	0.00457	CbGpPWpGaD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	0.000381	0.00455	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway—RHOA—urinary bladder cancer	0.000379	0.00453	CbGpPWpGaD
Amiloride—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.000374	0.00447	CbGpPWpGaD
Amiloride—SLC9A1—Carbohydrate metabolism—ENO2—urinary bladder cancer	0.00037	0.00442	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—CXCL8—urinary bladder cancer	0.000368	0.0044	CbGpPWpGaD
Amiloride—SLC22A4—lymph node—urinary bladder cancer	0.000358	0.00332	CbGeAlD
Amiloride—PLAU—FGF signaling pathway—MMP9—urinary bladder cancer	0.000358	0.00427	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—CDKN2A—urinary bladder cancer	0.000354	0.00423	CbGpPWpGaD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—EGFR—urinary bladder cancer	0.000353	0.00422	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—CCND1—urinary bladder cancer	0.000343	0.0041	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—CDKN2A—urinary bladder cancer	0.000343	0.00409	CbGpPWpGaD
Amiloride—ASIC2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000341	0.00407	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—SRC—urinary bladder cancer	0.00033	0.00394	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—ATM—urinary bladder cancer	0.000327	0.0039	CbGpPWpGaD
Amiloride—SLC9A1—G Protein Signaling Pathways—RHOA—urinary bladder cancer	0.000323	0.00386	CbGpPWpGaD
Amiloride—SLC9A1—Endothelins—SRC—urinary bladder cancer	0.000323	0.00386	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—CXCL8—urinary bladder cancer	0.000321	0.00384	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—EP300—urinary bladder cancer	0.000316	0.00377	CbGpPWpGaD
Amiloride—PLAU—Endochondral Ossification—MMP9—urinary bladder cancer	0.000312	0.00373	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway—CCND1—urinary bladder cancer	0.00031	0.0037	CbGpPWpGaD
Amiloride—SLC9A1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00031	0.0037	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—IL2—urinary bladder cancer	0.000307	0.00367	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—CREBBP—urinary bladder cancer	0.000299	0.00358	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—CCND1—urinary bladder cancer	0.000299	0.00358	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—RB1—urinary bladder cancer	0.000291	0.00348	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—MMP9—urinary bladder cancer	0.000291	0.00347	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—PTEN—urinary bladder cancer	0.000289	0.00345	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—IGF1—urinary bladder cancer	0.000289	0.00345	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—FGFR3—urinary bladder cancer	0.000288	0.00344	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—CDKN1A—urinary bladder cancer	0.00028	0.00334	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—EP300—urinary bladder cancer	0.000275	0.00329	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—RHOA—urinary bladder cancer	0.000271	0.00323	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—EP300—urinary bladder cancer	0.000266	0.00318	CbGpPWpGaD
Amiloride—SCNN1D—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000259	0.00309	CbGpPWpGaD
Amiloride—ASIC1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000259	0.00309	CbGpPWpGaD
Amiloride—SCNN1G—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000259	0.00309	CbGpPWpGaD
Amiloride—SCNN1A—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000259	0.00309	CbGpPWpGaD
Amiloride—SCNN1B—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000259	0.00309	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—RHOA—urinary bladder cancer	0.000257	0.00307	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—CDKN2A—urinary bladder cancer	0.000256	0.00306	CbGpPWpGaD
Amiloride—SLC9A1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000252	0.00301	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway—MYC—urinary bladder cancer	0.000249	0.00297	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CDKN2A—urinary bladder cancer	0.000249	0.00297	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—MYC—urinary bladder cancer	0.00024	0.00287	CbGpPWpGaD
Amiloride—SLC9A1—Disease—GSTO2—urinary bladder cancer	0.000239	0.00286	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—ERBB2—urinary bladder cancer	0.000238	0.00284	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—CXCL8—urinary bladder cancer	0.000232	0.00277	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—MYC—urinary bladder cancer	0.000232	0.00277	CbGpPWpGaD
Amiloride—SLC9A1—Endothelins—HRAS—urinary bladder cancer	0.000227	0.00272	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—RHOA—urinary bladder cancer	0.000222	0.00265	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—CCND1—urinary bladder cancer	0.000221	0.00265	CbGpPWpGaD
Amiloride—Paraesthesia—Thiotepa—urinary bladder cancer	0.000217	0.00268	CcSEcCtD
Amiloride—Alopecia—Etoposide—urinary bladder cancer	0.000216	0.00266	CcSEcCtD
Amiloride—Somnolence—Thiotepa—urinary bladder cancer	0.000215	0.00265	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—SRC—urinary bladder cancer	0.000215	0.00256	CbGpPWpGaD
Amiloride—Dyspepsia—Thiotepa—urinary bladder cancer	0.000213	0.00262	CcSEcCtD
Amiloride—Arthralgia—Gemcitabine—urinary bladder cancer	0.000212	0.00262	CcSEcCtD
Amiloride—Chest pain—Gemcitabine—urinary bladder cancer	0.000212	0.00262	CcSEcCtD
Amiloride—SLC9A1—Metabolism—GSTZ1—urinary bladder cancer	0.000212	0.00253	CbGpPWpGaD
Amiloride—Decreased appetite—Thiotepa—urinary bladder cancer	0.00021	0.00259	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CCND1—urinary bladder cancer	0.00021	0.00251	CbGpPWpGaD
Amiloride—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.00021	0.00259	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—CDKN1A—urinary bladder cancer	0.000209	0.0025	CbGpPWpGaD
Amiloride—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000209	0.00257	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—PTEN—urinary bladder cancer	0.000209	0.00249	CbGpPWpGaD
Amiloride—Chest pain—Fluorouracil—urinary bladder cancer	0.000209	0.00257	CcSEcCtD
Amiloride—Fatigue—Thiotepa—urinary bladder cancer	0.000209	0.00257	CcSEcCtD
Amiloride—Constipation—Thiotepa—urinary bladder cancer	0.000207	0.00255	CcSEcCtD
Amiloride—Pain—Thiotepa—urinary bladder cancer	0.000207	0.00255	CcSEcCtD
Amiloride—Back pain—Etoposide—urinary bladder cancer	0.000206	0.00254	CcSEcCtD
Amiloride—Muscle spasms—Etoposide—urinary bladder cancer	0.000205	0.00252	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—EP300—urinary bladder cancer	0.000204	0.00243	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CDKN1A—urinary bladder cancer	0.000203	0.00243	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—PTEN—urinary bladder cancer	0.000203	0.00242	CbGpPWpGaD
Amiloride—Confusional state—Fluorouracil—urinary bladder cancer	0.000202	0.00249	CcSEcCtD
Amiloride—SLC9A1—Metabolism—GSTO2—urinary bladder cancer	0.000201	0.0024	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—NAT1—urinary bladder cancer	0.000201	0.0024	CbGpPWpGaD
Amiloride—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000199	0.00246	CcSEcCtD
Amiloride—Hyponatraemia—Epirubicin—urinary bladder cancer	0.000199	0.00245	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Epirubicin—urinary bladder cancer	0.000198	0.00244	CcSEcCtD
Amiloride—Pain in extremity—Epirubicin—urinary bladder cancer	0.000198	0.00244	CcSEcCtD
Amiloride—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000198	0.00244	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—TP53—urinary bladder cancer	0.000197	0.00235	CbGpPWpGaD
Amiloride—SLC22A4—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000196	0.00234	CbGpPWpGaD
Amiloride—SLC9A1—G Protein Signaling Pathways—KRAS—urinary bladder cancer	0.000196	0.00234	CbGpPWpGaD
Amiloride—Anorexia—Gemcitabine—urinary bladder cancer	0.000194	0.00239	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—SRC—urinary bladder cancer	0.000194	0.00231	CbGpPWpGaD
Amiloride—Vertigo—Etoposide—urinary bladder cancer	0.000191	0.00236	CcSEcCtD
Amiloride—Abdominal pain—Thiotepa—urinary bladder cancer	0.000191	0.00236	CcSEcCtD
Amiloride—Anorexia—Fluorouracil—urinary bladder cancer	0.000191	0.00235	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—EGFR—urinary bladder cancer	0.000188	0.00225	CbGpPWpGaD
Amiloride—SLC9A1—Disease—SLC19A1—urinary bladder cancer	0.000186	0.00222	CbGpPWpGaD
Amiloride—Cough—Etoposide—urinary bladder cancer	0.000186	0.00229	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000185	0.00228	CcSEcCtD
Amiloride—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.000184	0.00227	CcSEcCtD
Amiloride—Insomnia—Gemcitabine—urinary bladder cancer	0.000184	0.00227	CcSEcCtD
Amiloride—SLC9A1—Metabolism—UGT2B7—urinary bladder cancer	0.000183	0.00219	CbGpPWpGaD
Amiloride—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	0.000183	0.00226	CcSEcCtD
Amiloride—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000183	0.00226	CcSEcCtD
Amiloride—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000183	0.00225	CcSEcCtD
Amiloride—SLC22A2—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000182	0.00218	CbGpPWpGaD
Amiloride—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000182	0.00225	CcSEcCtD
Amiloride—SLC9A1—Disease—PRSS3—urinary bladder cancer	0.000181	0.00217	CbGpPWpGaD
Amiloride—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000181	0.00224	CcSEcCtD
Amiloride—Chest pain—Etoposide—urinary bladder cancer	0.000181	0.00223	CcSEcCtD
Amiloride—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.000181	0.00223	CcSEcCtD
Amiloride—Insomnia—Fluorouracil—urinary bladder cancer	0.000181	0.00223	CcSEcCtD
Amiloride—Somnolence—Gemcitabine—urinary bladder cancer	0.000181	0.00223	CcSEcCtD
Amiloride—Anorexia—Cisplatin—urinary bladder cancer	0.000181	0.00223	CcSEcCtD
Amiloride—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00018	0.00221	CcSEcCtD
Amiloride—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000178	0.0022	CcSEcCtD
Amiloride—Somnolence—Fluorouracil—urinary bladder cancer	0.000178	0.00219	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—KRAS—urinary bladder cancer	0.000178	0.00212	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—MYC—urinary bladder cancer	0.000178	0.00212	CbGpPWpGaD
Amiloride—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000177	0.00218	CcSEcCtD
Amiloride—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000176	0.00217	CcSEcCtD
Amiloride—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000176	0.00216	CcSEcCtD
Amiloride—Fatigue—Gemcitabine—urinary bladder cancer	0.000175	0.00216	CcSEcCtD
Amiloride—Confusional state—Etoposide—urinary bladder cancer	0.000175	0.00216	CcSEcCtD
Amiloride—Muscular weakness—Epirubicin—urinary bladder cancer	0.000175	0.00215	CcSEcCtD
Amiloride—Pain—Gemcitabine—urinary bladder cancer	0.000174	0.00214	CcSEcCtD
Amiloride—Constipation—Gemcitabine—urinary bladder cancer	0.000174	0.00214	CcSEcCtD
Amiloride—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000174	0.00214	CcSEcCtD
Amiloride—Asthenia—Thiotepa—urinary bladder cancer	0.000174	0.00214	CcSEcCtD
Amiloride—SLC9A1—Disease—HDAC4—urinary bladder cancer	0.000173	0.00207	CbGpPWpGaD
Amiloride—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000173	0.00213	CcSEcCtD
Amiloride—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000173	0.00213	CcSEcCtD
Amiloride—Abdominal distension—Epirubicin—urinary bladder cancer	0.000172	0.00212	CcSEcCtD
Amiloride—Dysuria—Methotrexate—urinary bladder cancer	0.000171	0.00211	CcSEcCtD
Amiloride—Neutropenia—Methotrexate—urinary bladder cancer	0.000171	0.00211	CcSEcCtD
Amiloride—Pruritus—Thiotepa—urinary bladder cancer	0.000171	0.00211	CcSEcCtD
Amiloride—Pain—Fluorouracil—urinary bladder cancer	0.000171	0.00211	CcSEcCtD
Amiloride—SLC9A1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.00017	0.00204	CbGpPWpGaD
Amiloride—Paraesthesia—Cisplatin—urinary bladder cancer	0.00017	0.0021	CcSEcCtD
Amiloride—SLC22A1—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.00017	0.00203	CbGpPWpGaD
Amiloride—Dyspnoea—Cisplatin—urinary bladder cancer	0.000169	0.00208	CcSEcCtD
Amiloride—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000169	0.00208	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—MYC—urinary bladder cancer	0.000168	0.00201	CbGpPWpGaD
Amiloride—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000168	0.00207	CcSEcCtD
Amiloride—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000167	0.00206	CcSEcCtD
Amiloride—Angina pectoris—Epirubicin—urinary bladder cancer	0.000167	0.00206	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—HRAS—urinary bladder cancer	0.000167	0.00199	CbGpPWpGaD
Amiloride—Anorexia—Etoposide—urinary bladder cancer	0.000166	0.00204	CcSEcCtD
Amiloride—Diarrhoea—Thiotepa—urinary bladder cancer	0.000166	0.00204	CcSEcCtD
Amiloride—SLC9A1—Metabolism—CYP4B1—urinary bladder cancer	0.000165	0.00197	CbGpPWpGaD
Amiloride—Decreased appetite—Cisplatin—urinary bladder cancer	0.000165	0.00203	CcSEcCtD
Amiloride—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000165	0.00203	CcSEcCtD
Amiloride—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000164	0.00202	CcSEcCtD
Amiloride—Depression—Methotrexate—urinary bladder cancer	0.000163	0.002	CcSEcCtD
Amiloride—Pain—Cisplatin—urinary bladder cancer	0.000162	0.002	CcSEcCtD
Amiloride—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000162	0.00199	CcSEcCtD
Amiloride—Dysuria—Epirubicin—urinary bladder cancer	0.00016	0.00197	CcSEcCtD
Amiloride—Neutropenia—Epirubicin—urinary bladder cancer	0.00016	0.00197	CcSEcCtD
Amiloride—Dizziness—Thiotepa—urinary bladder cancer	0.00016	0.00197	CcSEcCtD
Amiloride—ASIC2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.00016	0.00191	CbGpPWpGaD
Amiloride—Abdominal distension—Doxorubicin—urinary bladder cancer	0.00016	0.00197	CcSEcCtD
Amiloride—Pollakiuria—Epirubicin—urinary bladder cancer	0.000158	0.00195	CcSEcCtD
Amiloride—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000156	0.00193	CcSEcCtD
Amiloride—Paraesthesia—Etoposide—urinary bladder cancer	0.000156	0.00192	CcSEcCtD
Amiloride—SLC9A1—Metabolism—SLC19A1—urinary bladder cancer	0.000156	0.00186	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—KRAS—urinary bladder cancer	0.000156	0.00186	CbGpPWpGaD
Amiloride—Dyspnoea—Etoposide—urinary bladder cancer	0.000155	0.00191	CcSEcCtD
Amiloride—Somnolence—Etoposide—urinary bladder cancer	0.000154	0.0019	CcSEcCtD
Amiloride—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000154	0.0019	CcSEcCtD
Amiloride—Vomiting—Thiotepa—urinary bladder cancer	0.000154	0.00189	CcSEcCtD
Amiloride—Rash—Thiotepa—urinary bladder cancer	0.000153	0.00188	CcSEcCtD
Amiloride—Dermatitis—Thiotepa—urinary bladder cancer	0.000152	0.00188	CcSEcCtD
Amiloride—SLC9A1—Metabolism—PRSS3—urinary bladder cancer	0.000152	0.00182	CbGpPWpGaD
Amiloride—Headache—Thiotepa—urinary bladder cancer	0.000152	0.00187	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—HRAS—urinary bladder cancer	0.000151	0.00181	CbGpPWpGaD
Amiloride—Decreased appetite—Etoposide—urinary bladder cancer	0.000151	0.00186	CcSEcCtD
Amiloride—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00015	0.00185	CcSEcCtD
Amiloride—Fatigue—Etoposide—urinary bladder cancer	0.00015	0.00185	CcSEcCtD
Amiloride—Jaundice—Epirubicin—urinary bladder cancer	0.000149	0.00183	CcSEcCtD
Amiloride—Constipation—Etoposide—urinary bladder cancer	0.000149	0.00183	CcSEcCtD
Amiloride—Pain—Etoposide—urinary bladder cancer	0.000149	0.00183	CcSEcCtD
Amiloride—Neutropenia—Doxorubicin—urinary bladder cancer	0.000148	0.00183	CcSEcCtD
Amiloride—Dysuria—Doxorubicin—urinary bladder cancer	0.000148	0.00183	CcSEcCtD
Amiloride—Haemoglobin—Methotrexate—urinary bladder cancer	0.000147	0.00181	CcSEcCtD
Amiloride—Haemorrhage—Methotrexate—urinary bladder cancer	0.000147	0.0018	CcSEcCtD
Amiloride—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000146	0.0018	CcSEcCtD
Amiloride—Asthenia—Gemcitabine—urinary bladder cancer	0.000146	0.0018	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—TP53—urinary bladder cancer	0.000146	0.00174	CbGpPWpGaD
Amiloride—Pruritus—Gemcitabine—urinary bladder cancer	0.000144	0.00177	CcSEcCtD
Amiloride—Nausea—Thiotepa—urinary bladder cancer	0.000144	0.00177	CcSEcCtD
Amiloride—Feeling abnormal—Etoposide—urinary bladder cancer	0.000143	0.00176	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—TP53—urinary bladder cancer	0.000143	0.0017	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—EGFR—urinary bladder cancer	0.000142	0.0017	CbGpPWpGaD
Amiloride—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000142	0.00175	CcSEcCtD
Amiloride—PLAU—Hemostasis—IFNA2—urinary bladder cancer	0.000142	0.0017	CbGpPWpGaD
Amiloride—SLC22A4—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000142	0.00169	CbGpPWpGaD
Amiloride—Pruritus—Fluorouracil—urinary bladder cancer	0.000142	0.00174	CcSEcCtD
Amiloride—Visual impairment—Methotrexate—urinary bladder cancer	0.000141	0.00174	CcSEcCtD
Amiloride—Bradycardia—Epirubicin—urinary bladder cancer	0.00014	0.00172	CcSEcCtD
Amiloride—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000139	0.00172	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—TP53—urinary bladder cancer	0.000138	0.00165	CbGpPWpGaD
Amiloride—Haemoglobin—Epirubicin—urinary bladder cancer	0.000138	0.0017	CcSEcCtD
Amiloride—Jaundice—Doxorubicin—urinary bladder cancer	0.000138	0.0017	CcSEcCtD
Amiloride—SLC9A1—Disease—LIG1—urinary bladder cancer	0.000138	0.00164	CbGpPWpGaD
Amiloride—Abdominal pain—Etoposide—urinary bladder cancer	0.000137	0.00169	CcSEcCtD
Amiloride—Haemorrhage—Epirubicin—urinary bladder cancer	0.000137	0.00169	CcSEcCtD
Amiloride—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000137	0.00169	CcSEcCtD
Amiloride—Tinnitus—Methotrexate—urinary bladder cancer	0.000137	0.00168	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—HRAS—urinary bladder cancer	0.000136	0.00163	CbGpPWpGaD
Amiloride—Asthenia—Cisplatin—urinary bladder cancer	0.000136	0.00168	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—KRAS—urinary bladder cancer	0.000134	0.00161	CbGpPWpGaD
Amiloride—Dizziness—Fluorouracil—urinary bladder cancer	0.000132	0.00163	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—HRAS—urinary bladder cancer	0.000132	0.00158	CbGpPWpGaD
Amiloride—Visual impairment—Epirubicin—urinary bladder cancer	0.000132	0.00163	CcSEcCtD
Amiloride—Diarrhoea—Cisplatin—urinary bladder cancer	0.00013	0.0016	CcSEcCtD
Amiloride—Alopecia—Methotrexate—urinary bladder cancer	0.000129	0.00159	CcSEcCtD
Amiloride—Vomiting—Gemcitabine—urinary bladder cancer	0.000129	0.00159	CcSEcCtD
Amiloride—Bradycardia—Doxorubicin—urinary bladder cancer	0.000129	0.00159	CcSEcCtD
Amiloride—Rash—Gemcitabine—urinary bladder cancer	0.000128	0.00158	CcSEcCtD
Amiloride—Dermatitis—Gemcitabine—urinary bladder cancer	0.000128	0.00158	CcSEcCtD
Amiloride—Tinnitus—Epirubicin—urinary bladder cancer	0.000128	0.00157	CcSEcCtD
Amiloride—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000128	0.00157	CcSEcCtD
Amiloride—Headache—Gemcitabine—urinary bladder cancer	0.000127	0.00157	CcSEcCtD
Amiloride—Vomiting—Fluorouracil—urinary bladder cancer	0.000127	0.00157	CcSEcCtD
Amiloride—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000127	0.00156	CcSEcCtD
Amiloride—Rash—Fluorouracil—urinary bladder cancer	0.000126	0.00155	CcSEcCtD
Amiloride—Dermatitis—Fluorouracil—urinary bladder cancer	0.000126	0.00155	CcSEcCtD
Amiloride—Headache—Fluorouracil—urinary bladder cancer	0.000125	0.00154	CcSEcCtD
Amiloride—Asthenia—Etoposide—urinary bladder cancer	0.000125	0.00154	CcSEcCtD
Amiloride—Back pain—Methotrexate—urinary bladder cancer	0.000123	0.00152	CcSEcCtD
Amiloride—Pruritus—Etoposide—urinary bladder cancer	0.000123	0.00151	CcSEcCtD
Amiloride—Visual impairment—Doxorubicin—urinary bladder cancer	0.000122	0.00151	CcSEcCtD
Amiloride—SLC9A1—Metabolism—TYMP—urinary bladder cancer	0.000121	0.00145	CbGpPWpGaD
Amiloride—Alopecia—Epirubicin—urinary bladder cancer	0.000121	0.00149	CcSEcCtD
Amiloride—SCNN1B—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000121	0.00145	CbGpPWpGaD
Amiloride—SCNN1D—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000121	0.00145	CbGpPWpGaD
Amiloride—ASIC1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000121	0.00145	CbGpPWpGaD
Amiloride—SCNN1G—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000121	0.00145	CbGpPWpGaD
Amiloride—SCNN1A—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000121	0.00145	CbGpPWpGaD
Amiloride—Nausea—Gemcitabine—urinary bladder cancer	0.000121	0.00149	CcSEcCtD
Amiloride—Vomiting—Cisplatin—urinary bladder cancer	0.000121	0.00149	CcSEcCtD
Amiloride—Rash—Cisplatin—urinary bladder cancer	0.00012	0.00147	CcSEcCtD
Amiloride—Dermatitis—Cisplatin—urinary bladder cancer	0.000119	0.00147	CcSEcCtD
Amiloride—Diarrhoea—Etoposide—urinary bladder cancer	0.000119	0.00146	CcSEcCtD
Amiloride—Nausea—Fluorouracil—urinary bladder cancer	0.000119	0.00146	CcSEcCtD
Amiloride—Tinnitus—Doxorubicin—urinary bladder cancer	0.000118	0.00146	CcSEcCtD
Amiloride—Flatulence—Epirubicin—urinary bladder cancer	0.000118	0.00145	CcSEcCtD
Amiloride—Tension—Epirubicin—urinary bladder cancer	0.000117	0.00144	CcSEcCtD
Amiloride—Nervousness—Epirubicin—urinary bladder cancer	0.000116	0.00143	CcSEcCtD
Amiloride—SLC22A4—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000115	0.00138	CbGpPWpGaD
Amiloride—Back pain—Epirubicin—urinary bladder cancer	0.000115	0.00142	CcSEcCtD
Amiloride—Dizziness—Etoposide—urinary bladder cancer	0.000115	0.00142	CcSEcCtD
Amiloride—Muscle spasms—Epirubicin—urinary bladder cancer	0.000115	0.00141	CcSEcCtD
Amiloride—Vertigo—Methotrexate—urinary bladder cancer	0.000115	0.00141	CcSEcCtD
Amiloride—Nausea—Cisplatin—urinary bladder cancer	0.000113	0.00139	CcSEcCtD
Amiloride—Alopecia—Doxorubicin—urinary bladder cancer	0.000112	0.00138	CcSEcCtD
Amiloride—Cough—Methotrexate—urinary bladder cancer	0.000111	0.00137	CcSEcCtD
Amiloride—Vomiting—Etoposide—urinary bladder cancer	0.00011	0.00136	CcSEcCtD
Amiloride—SLC9A1—Metabolism—NAT2—urinary bladder cancer	0.00011	0.00131	CbGpPWpGaD
Amiloride—Rash—Etoposide—urinary bladder cancer	0.00011	0.00135	CcSEcCtD
Amiloride—Dermatitis—Etoposide—urinary bladder cancer	0.000109	0.00135	CcSEcCtD
Amiloride—Headache—Etoposide—urinary bladder cancer	0.000109	0.00134	CcSEcCtD
Amiloride—Flatulence—Doxorubicin—urinary bladder cancer	0.000109	0.00134	CcSEcCtD
Amiloride—Chest pain—Methotrexate—urinary bladder cancer	0.000109	0.00134	CcSEcCtD
Amiloride—Arthralgia—Methotrexate—urinary bladder cancer	0.000109	0.00134	CcSEcCtD
Amiloride—Tension—Doxorubicin—urinary bladder cancer	0.000108	0.00134	CcSEcCtD
Amiloride—Nervousness—Doxorubicin—urinary bladder cancer	0.000107	0.00132	CcSEcCtD
Amiloride—Vertigo—Epirubicin—urinary bladder cancer	0.000107	0.00132	CcSEcCtD
Amiloride—Back pain—Doxorubicin—urinary bladder cancer	0.000107	0.00132	CcSEcCtD
Amiloride—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000106	0.00131	CcSEcCtD
Amiloride—Palpitations—Epirubicin—urinary bladder cancer	0.000105	0.0013	CcSEcCtD
Amiloride—Confusional state—Methotrexate—urinary bladder cancer	0.000105	0.00129	CcSEcCtD
Amiloride—SLC9A1—Disease—ENO2—urinary bladder cancer	0.000105	0.00125	CbGpPWpGaD
Amiloride—Cough—Epirubicin—urinary bladder cancer	0.000104	0.00128	CcSEcCtD
Amiloride—Nausea—Etoposide—urinary bladder cancer	0.000103	0.00127	CcSEcCtD
Amiloride—Arthralgia—Epirubicin—urinary bladder cancer	0.000102	0.00125	CcSEcCtD
Amiloride—Chest pain—Epirubicin—urinary bladder cancer	0.000102	0.00125	CcSEcCtD
Amiloride—SLC9A1—Disease—RBX1—urinary bladder cancer	9.94e-05	0.00119	CbGpPWpGaD
Amiloride—Vertigo—Doxorubicin—urinary bladder cancer	9.92e-05	0.00122	CcSEcCtD
Amiloride—Anorexia—Methotrexate—urinary bladder cancer	9.92e-05	0.00122	CcSEcCtD
Amiloride—Confusional state—Epirubicin—urinary bladder cancer	9.82e-05	0.00121	CcSEcCtD
Amiloride—Palpitations—Doxorubicin—urinary bladder cancer	9.76e-05	0.0012	CcSEcCtD
Amiloride—Cough—Doxorubicin—urinary bladder cancer	9.64e-05	0.00119	CcSEcCtD
Amiloride—Shock—Epirubicin—urinary bladder cancer	9.58e-05	0.00118	CcSEcCtD
Amiloride—SLC9A1—Metabolism—RRM2—urinary bladder cancer	9.48e-05	0.00113	CbGpPWpGaD
Amiloride—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	9.48e-05	0.00117	CcSEcCtD
Amiloride—Insomnia—Methotrexate—urinary bladder cancer	9.41e-05	0.00116	CcSEcCtD
Amiloride—Chest pain—Doxorubicin—urinary bladder cancer	9.4e-05	0.00116	CcSEcCtD
Amiloride—Arthralgia—Doxorubicin—urinary bladder cancer	9.4e-05	0.00116	CcSEcCtD
Amiloride—Paraesthesia—Methotrexate—urinary bladder cancer	9.35e-05	0.00115	CcSEcCtD
Amiloride—Anorexia—Epirubicin—urinary bladder cancer	9.29e-05	0.00114	CcSEcCtD
Amiloride—Dyspnoea—Methotrexate—urinary bladder cancer	9.28e-05	0.00114	CcSEcCtD
Amiloride—SLC22A2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	9.27e-05	0.00111	CbGpPWpGaD
Amiloride—Somnolence—Methotrexate—urinary bladder cancer	9.25e-05	0.00114	CcSEcCtD
Amiloride—Dyspepsia—Methotrexate—urinary bladder cancer	9.16e-05	0.00113	CcSEcCtD
Amiloride—Confusional state—Doxorubicin—urinary bladder cancer	9.09e-05	0.00112	CcSEcCtD
Amiloride—Decreased appetite—Methotrexate—urinary bladder cancer	9.05e-05	0.00111	CcSEcCtD
Amiloride—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	8.99e-05	0.00111	CcSEcCtD
Amiloride—Fatigue—Methotrexate—urinary bladder cancer	8.97e-05	0.00111	CcSEcCtD
Amiloride—Pain—Methotrexate—urinary bladder cancer	8.9e-05	0.0011	CcSEcCtD
Amiloride—SLC9A1—Disease—JAG1—urinary bladder cancer	8.9e-05	0.00106	CbGpPWpGaD
Amiloride—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	8.88e-05	0.00109	CcSEcCtD
Amiloride—Shock—Doxorubicin—urinary bladder cancer	8.87e-05	0.00109	CcSEcCtD
Amiloride—Insomnia—Epirubicin—urinary bladder cancer	8.81e-05	0.00109	CcSEcCtD
Amiloride—SLC9A1—Metabolism—ENO2—urinary bladder cancer	8.78e-05	0.00105	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—HPGDS—urinary bladder cancer	8.78e-05	0.00105	CbGpPWpGaD
Amiloride—Paraesthesia—Epirubicin—urinary bladder cancer	8.75e-05	0.00108	CcSEcCtD
Amiloride—Dyspnoea—Epirubicin—urinary bladder cancer	8.68e-05	0.00107	CcSEcCtD
Amiloride—Somnolence—Epirubicin—urinary bladder cancer	8.66e-05	0.00107	CcSEcCtD
Amiloride—SLC22A1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	8.64e-05	0.00103	CbGpPWpGaD
Amiloride—Anorexia—Doxorubicin—urinary bladder cancer	8.59e-05	0.00106	CcSEcCtD
Amiloride—Feeling abnormal—Methotrexate—urinary bladder cancer	8.58e-05	0.00106	CcSEcCtD
Amiloride—Dyspepsia—Epirubicin—urinary bladder cancer	8.57e-05	0.00106	CcSEcCtD
Amiloride—SLC9A1—Metabolism—GSTT1—urinary bladder cancer	8.52e-05	0.00102	CbGpPWpGaD
Amiloride—Gastrointestinal pain—Methotrexate—urinary bladder cancer	8.51e-05	0.00105	CcSEcCtD
Amiloride—Decreased appetite—Epirubicin—urinary bladder cancer	8.47e-05	0.00104	CcSEcCtD
Amiloride—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.41e-05	0.00104	CcSEcCtD
Amiloride—Fatigue—Epirubicin—urinary bladder cancer	8.4e-05	0.00103	CcSEcCtD
Amiloride—Constipation—Epirubicin—urinary bladder cancer	8.33e-05	0.00103	CcSEcCtD
Amiloride—Pain—Epirubicin—urinary bladder cancer	8.33e-05	0.00103	CcSEcCtD
Amiloride—PLAU—Hemostasis—CREBBP—urinary bladder cancer	8.31e-05	0.000993	CbGpPWpGaD
Amiloride—Abdominal pain—Methotrexate—urinary bladder cancer	8.23e-05	0.00101	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	8.21e-05	0.00101	CcSEcCtD
Amiloride—PLAU—Hemostasis—IGF1—urinary bladder cancer	8.21e-05	0.00098	CbGpPWpGaD
Amiloride—Insomnia—Doxorubicin—urinary bladder cancer	8.15e-05	0.001	CcSEcCtD
Amiloride—Paraesthesia—Doxorubicin—urinary bladder cancer	8.09e-05	0.000997	CcSEcCtD
Amiloride—Dyspnoea—Doxorubicin—urinary bladder cancer	8.04e-05	0.00099	CcSEcCtD
Amiloride—Feeling abnormal—Epirubicin—urinary bladder cancer	8.03e-05	0.000989	CcSEcCtD
Amiloride—Somnolence—Doxorubicin—urinary bladder cancer	8.01e-05	0.000987	CcSEcCtD
Amiloride—SLC9A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.98e-05	0.000953	CbGpPWpGaD
Amiloride—Gastrointestinal pain—Epirubicin—urinary bladder cancer	7.97e-05	0.000981	CcSEcCtD
Amiloride—Dyspepsia—Doxorubicin—urinary bladder cancer	7.93e-05	0.000977	CcSEcCtD
Amiloride—Decreased appetite—Doxorubicin—urinary bladder cancer	7.84e-05	0.000965	CcSEcCtD
Amiloride—SLC22A4—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	7.8e-05	0.000932	CbGpPWpGaD
Amiloride—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7.78e-05	0.000959	CcSEcCtD
Amiloride—Fatigue—Doxorubicin—urinary bladder cancer	7.77e-05	0.000957	CcSEcCtD
Amiloride—Pain—Doxorubicin—urinary bladder cancer	7.71e-05	0.00095	CcSEcCtD
Amiloride—Constipation—Doxorubicin—urinary bladder cancer	7.71e-05	0.00095	CcSEcCtD
Amiloride—Abdominal pain—Epirubicin—urinary bladder cancer	7.7e-05	0.000949	CcSEcCtD
Amiloride—PLAU—Hemostasis—RHOA—urinary bladder cancer	7.52e-05	0.000898	CbGpPWpGaD
Amiloride—Asthenia—Methotrexate—urinary bladder cancer	7.47e-05	0.00092	CcSEcCtD
Amiloride—Feeling abnormal—Doxorubicin—urinary bladder cancer	7.43e-05	0.000915	CcSEcCtD
Amiloride—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	7.37e-05	0.000908	CcSEcCtD
Amiloride—Pruritus—Methotrexate—urinary bladder cancer	7.36e-05	0.000907	CcSEcCtD
Amiloride—Abdominal pain—Doxorubicin—urinary bladder cancer	7.13e-05	0.000878	CcSEcCtD
Amiloride—Diarrhoea—Methotrexate—urinary bladder cancer	7.12e-05	0.000877	CcSEcCtD
Amiloride—SLC9A1—Metabolism—NQO1—urinary bladder cancer	7.08e-05	0.000846	CbGpPWpGaD
Amiloride—Asthenia—Epirubicin—urinary bladder cancer	6.99e-05	0.000861	CcSEcCtD
Amiloride—Pruritus—Epirubicin—urinary bladder cancer	6.89e-05	0.000849	CcSEcCtD
Amiloride—Dizziness—Methotrexate—urinary bladder cancer	6.88e-05	0.000848	CcSEcCtD
Amiloride—SLC22A2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	6.7e-05	0.0008	CbGpPWpGaD
Amiloride—Diarrhoea—Epirubicin—urinary bladder cancer	6.67e-05	0.000821	CcSEcCtD
Amiloride—Vomiting—Methotrexate—urinary bladder cancer	6.62e-05	0.000815	CcSEcCtD
Amiloride—Rash—Methotrexate—urinary bladder cancer	6.56e-05	0.000809	CcSEcCtD
Amiloride—Dermatitis—Methotrexate—urinary bladder cancer	6.56e-05	0.000808	CcSEcCtD
Amiloride—Headache—Methotrexate—urinary bladder cancer	6.52e-05	0.000803	CcSEcCtD
Amiloride—SLC9A1—Disease—NCOR1—urinary bladder cancer	6.48e-05	0.000774	CbGpPWpGaD
Amiloride—Asthenia—Doxorubicin—urinary bladder cancer	6.47e-05	0.000797	CcSEcCtD
Amiloride—Dizziness—Epirubicin—urinary bladder cancer	6.44e-05	0.000794	CcSEcCtD
Amiloride—Pruritus—Doxorubicin—urinary bladder cancer	6.38e-05	0.000786	CcSEcCtD
Amiloride—PLAU—Hemostasis—IL2—urinary bladder cancer	6.31e-05	0.000754	CbGpPWpGaD
Amiloride—SLC22A1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	6.24e-05	0.000746	CbGpPWpGaD
Amiloride—Vomiting—Epirubicin—urinary bladder cancer	6.19e-05	0.000763	CcSEcCtD
Amiloride—Nausea—Methotrexate—urinary bladder cancer	6.18e-05	0.000762	CcSEcCtD
Amiloride—Diarrhoea—Doxorubicin—urinary bladder cancer	6.17e-05	0.00076	CcSEcCtD
Amiloride—Rash—Epirubicin—urinary bladder cancer	6.14e-05	0.000757	CcSEcCtD
Amiloride—Dermatitis—Epirubicin—urinary bladder cancer	6.14e-05	0.000756	CcSEcCtD
Amiloride—Headache—Epirubicin—urinary bladder cancer	6.1e-05	0.000752	CcSEcCtD
Amiloride—SLC9A1—Disease—ERCC2—urinary bladder cancer	6.09e-05	0.000728	CbGpPWpGaD
Amiloride—Dizziness—Doxorubicin—urinary bladder cancer	5.96e-05	0.000734	CcSEcCtD
Amiloride—SLC9A1—Metabolism—GSTP1—urinary bladder cancer	5.9e-05	0.000705	CbGpPWpGaD
Amiloride—Nausea—Epirubicin—urinary bladder cancer	5.79e-05	0.000713	CcSEcCtD
Amiloride—Vomiting—Doxorubicin—urinary bladder cancer	5.73e-05	0.000706	CcSEcCtD
Amiloride—SLC9A1—Disease—MTHFR—urinary bladder cancer	5.73e-05	0.000684	CbGpPWpGaD
Amiloride—SLC9A1—Disease—TERT—urinary bladder cancer	5.71e-05	0.000682	CbGpPWpGaD
Amiloride—Rash—Doxorubicin—urinary bladder cancer	5.68e-05	0.0007	CcSEcCtD
Amiloride—Dermatitis—Doxorubicin—urinary bladder cancer	5.68e-05	0.000699	CcSEcCtD
Amiloride—PLAU—Hemostasis—EP300—urinary bladder cancer	5.66e-05	0.000676	CbGpPWpGaD
Amiloride—Headache—Doxorubicin—urinary bladder cancer	5.65e-05	0.000696	CcSEcCtD
Amiloride—PLAU—Hemostasis—SRC—urinary bladder cancer	5.5e-05	0.000658	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—TYMS—urinary bladder cancer	5.49e-05	0.000656	CbGpPWpGaD
Amiloride—SLC22A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	5.46e-05	0.000652	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—GSTM1—urinary bladder cancer	5.43e-05	0.000648	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—NCOR1—urinary bladder cancer	5.43e-05	0.000648	CbGpPWpGaD
Amiloride—Nausea—Doxorubicin—urinary bladder cancer	5.35e-05	0.00066	CcSEcCtD
Amiloride—SLC9A1—Disease—FGFR3—urinary bladder cancer	5.24e-05	0.000626	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—GPX1—urinary bladder cancer	5.2e-05	0.000621	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—ERCC2—urinary bladder cancer	5.1e-05	0.000609	CbGpPWpGaD
Amiloride—SLC22A1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	5.09e-05	0.000608	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—MTHFR—urinary bladder cancer	4.8e-05	0.000573	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—GSTZ1—urinary bladder cancer	4.58e-05	0.000547	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—KRAS—urinary bladder cancer	4.56e-05	0.000544	CbGpPWpGaD
Amiloride—SLC9A1—Disease—CREBBP—urinary bladder cancer	4.46e-05	0.000533	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—NAT1—urinary bladder cancer	4.34e-05	0.000518	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—GSTO2—urinary bladder cancer	4.34e-05	0.000518	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—GSTZ1—urinary bladder cancer	4.27e-05	0.00051	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—TP53—urinary bladder cancer	4.05e-05	0.000484	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—GSTO2—urinary bladder cancer	4.05e-05	0.000483	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—NAT1—urinary bladder cancer	4.05e-05	0.000483	CbGpPWpGaD
Amiloride—SLC9A1—Disease—RHOA—urinary bladder cancer	4.04e-05	0.000482	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—UGT2B7—urinary bladder cancer	3.97e-05	0.000474	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PPARG—urinary bladder cancer	3.89e-05	0.000465	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—HRAS—urinary bladder cancer	3.87e-05	0.000463	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—CREBBP—urinary bladder cancer	3.74e-05	0.000446	CbGpPWpGaD
Amiloride—SLC9A1—Disease—ERBB2—urinary bladder cancer	3.74e-05	0.000446	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—UGT2B7—urinary bladder cancer	3.7e-05	0.000442	CbGpPWpGaD
Amiloride—SLC22A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.69e-05	0.000441	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PTGS2—urinary bladder cancer	3.65e-05	0.000436	CbGpPWpGaD
Amiloride—SLC22A4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.65e-05	0.000436	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—CYP4B1—urinary bladder cancer	3.57e-05	0.000427	CbGpPWpGaD
Amiloride—SLC22A1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.44e-05	0.000411	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—SLC19A1—urinary bladder cancer	3.38e-05	0.000403	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—CYP4B1—urinary bladder cancer	3.33e-05	0.000398	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PRSS3—urinary bladder cancer	3.29e-05	0.000393	CbGpPWpGaD
Amiloride—SLC9A1—Disease—CDKN1A—urinary bladder cancer	3.19e-05	0.000381	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PTEN—urinary bladder cancer	3.19e-05	0.000381	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—SLC19A1—urinary bladder cancer	3.15e-05	0.000376	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PRSS3—urinary bladder cancer	3.07e-05	0.000366	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PTGS2—urinary bladder cancer	3.06e-05	0.000365	CbGpPWpGaD
Amiloride—SLC9A1—Disease—EP300—urinary bladder cancer	3.04e-05	0.000363	CbGpPWpGaD
Amiloride—SLC9A1—Disease—SRC—urinary bladder cancer	2.95e-05	0.000353	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PTEN—urinary bladder cancer	2.67e-05	0.000319	CbGpPWpGaD
Amiloride—SLC9A1—Disease—MYC—urinary bladder cancer	2.65e-05	0.000316	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—TYMP—urinary bladder cancer	2.63e-05	0.000314	CbGpPWpGaD
Amiloride—SLC9A1—Disease—EGFR—urinary bladder cancer	2.59e-05	0.000309	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—EP300—urinary bladder cancer	2.54e-05	0.000304	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—TYMP—urinary bladder cancer	2.45e-05	0.000293	CbGpPWpGaD
Amiloride—SLC9A1—Disease—KRAS—urinary bladder cancer	2.45e-05	0.000292	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—NAT2—urinary bladder cancer	2.38e-05	0.000284	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—NAT2—urinary bladder cancer	2.22e-05	0.000265	CbGpPWpGaD
Amiloride—SLC9A1—Disease—HRAS—urinary bladder cancer	2.08e-05	0.000248	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—RRM2—urinary bladder cancer	2.05e-05	0.000245	CbGpPWpGaD
Amiloride—SLC22A2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.95e-05	0.000233	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—RRM2—urinary bladder cancer	1.91e-05	0.000229	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—ENO2—urinary bladder cancer	1.9e-05	0.000227	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—HPGDS—urinary bladder cancer	1.9e-05	0.000227	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—GSTT1—urinary bladder cancer	1.84e-05	0.00022	CbGpPWpGaD
Amiloride—SLC22A1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.82e-05	0.000217	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—HPGDS—urinary bladder cancer	1.77e-05	0.000212	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—ENO2—urinary bladder cancer	1.77e-05	0.000212	CbGpPWpGaD
Amiloride—SLC22A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.73e-05	0.000206	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—GSTT1—urinary bladder cancer	1.72e-05	0.000205	CbGpPWpGaD
Amiloride—SLC22A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.61e-05	0.000192	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—NQO1—urinary bladder cancer	1.53e-05	0.000183	CbGpPWpGaD
Amiloride—SLC22A2—Neuronal System—HRAS—urinary bladder cancer	1.5e-05	0.000179	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—NQO1—urinary bladder cancer	1.43e-05	0.000171	CbGpPWpGaD
Amiloride—SLC22A1—Neuronal System—HRAS—urinary bladder cancer	1.39e-05	0.000167	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—GSTP1—urinary bladder cancer	1.28e-05	0.000153	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—GSTP1—urinary bladder cancer	1.19e-05	0.000142	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—TYMS—urinary bladder cancer	1.19e-05	0.000142	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—NCOR1—urinary bladder cancer	1.17e-05	0.00014	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—GSTM1—urinary bladder cancer	1.17e-05	0.00014	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—GPX1—urinary bladder cancer	1.12e-05	0.000134	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—TYMS—urinary bladder cancer	1.11e-05	0.000132	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—ERCC2—urinary bladder cancer	1.1e-05	0.000132	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—NCOR1—urinary bladder cancer	1.09e-05	0.000131	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—GSTM1—urinary bladder cancer	1.09e-05	0.000131	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—GPX1—urinary bladder cancer	1.05e-05	0.000125	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—MTHFR—urinary bladder cancer	1.04e-05	0.000124	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—ERCC2—urinary bladder cancer	1.03e-05	0.000123	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—MTHFR—urinary bladder cancer	9.67e-06	0.000116	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PPARG—urinary bladder cancer	8.42e-06	0.000101	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	8.09e-06	9.66e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PPARG—urinary bladder cancer	7.85e-06	9.37e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	7.54e-06	9e-05	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	6.62e-06	7.91e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	6.17e-06	7.37e-05	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PTEN—urinary bladder cancer	5.77e-06	6.9e-05	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—EP300—urinary bladder cancer	5.51e-06	6.58e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PTEN—urinary bladder cancer	5.38e-06	6.43e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—EP300—urinary bladder cancer	5.13e-06	6.13e-05	CbGpPWpGaD
